MeiraGTx Holdings plc
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
MGTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- KYG596651029
- LEI:
- Country:
- United States of America
- Address:
- 655 THIRD AVENUE, 10017 NEW YORK
- Website:
- https://meiragtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
MeiraGTx Holdings plc is a clinical-stage genetic medicine company focused on developing treatments for a range of inherited and acquired disorders, including rare and prevalent diseases. The company's development pipeline targets conditions affecting the eye, salivary gland, and central nervous system. MeiraGTx pioneers technologies for precision control of gene expression, notably its proprietary riboswitch gene regulation platform, which allows for spatial and temporal control of transgene expression. As a vertically integrated company, it maintains a flexible genetic medicine platform and an end-to-end manufacturing ecosystem to support its clinical programs, several of which are in late-stage development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MeiraGTx Holdings plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MeiraGTx Holdings plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MeiraGTx Holdings plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
